SHLD1

Across TCGA pan-cancer cohorts, SHLD1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SHLD1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SHLD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHLD1 expression acts as an unfavorable survival marker.

STAD, KICH, and GBM are the cancer types where SHLD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.094	0.677	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
GBM	OS	Median	All	0.075	0.413	.003	6	view →
COAD	OS	Median	All	0.280	0.806	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SHLD1–STAD (OS)

Open the STAD breakdown →